Event Online Global FinTech Fest 2020 

 29 days ago
 Source: finsmes.com

Atlas Venture Closes Fund XII, at $400M

Quick Summary

Atlas Venture, a Cambridge, Mass.-based early stage venture capital firm investing in biotech innovation, closed its twelfth fund, at $400m. Atlas Venture will continue to focus on building biotech companies to deliver high-impact therapies to patients. With the closing of Fund XII, Michael Gladstone was promoted to partner. Gladstone joined Atlas in 2012 and has been a key contributor to many portfolio companies over the last eight years, including Akero, AVROBIO, Delinia, IFM, and others. Alongside Gladstone, the six investing partners in Fund XII also include Jason Rhodes, Bruce Booth, Kevin Bitterman, Jean-François Formela, and David Grayzel.

Disclaimer: This story is auto-aggregated & summarized by a computer program and has not been created by StartupAround.

Read Original Article

Popular Topics

Get the best stories from Startup Around on Telegram